Evidence mapPaperPMID 40362334Full record

ArticleInternational journal of molecular sciences2025

High Copy Number Variations Correlate with a Pro-Tumoral Microenvironment and Worse Prognosis in Acral Lentiginous Melanoma.

Inés de la Rosa, Pol Sisó, Christopher Ríos, Judith Gracia, Dolors Cuevas, Oscar Maiques, Núria Eritja, Xavier Soria, Joan Angel-Baldó, Sonia Gatius and 5 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Inés de la RosaOncologic Pathology Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.
Pol SisóOncologic Pathology Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.ORCID 0000-0002-3079-1793
Christopher RíosOncologic Pathology Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.ORCID 0009-0008-3902-1593
Judith GraciaOncologic Pathology Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.
Dolors CuevasOncologic Pathology Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.
Oscar MaiquesCytoskeleton and Cancer Metastasis Group, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SM2 5NG, UK.ORCID 0000-0002-2172-4388
Núria EritjaOncologic Pathology Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.
Xavier SoriaDepartment of Dermatology, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.
Joan Angel-BaldóDepartment of Dermatology, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.ORCID 0000-0002-8855-5646
Sonia GatiusOncologic Pathology Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.
Lidia Sanchez-MoralInnate Immunity Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain.ORCID 0000-0002-3795-8015
Maria-Rosa SarriasInnate Immunity Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain.ORCID 0000-0001-6929-8069
Xavier Matias-GuiuOncologic Pathology Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.ORCID 0000-0002-7201-6605
Rosa M MartíOncologic Pathology Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.ORCID 0000-0001-6866-6114
Anna MaciàOncologic Pathology Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, 25198 Lleida, Spain.ORCID 0000-0001-6038-178X

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2021_SGR_00093Agència de Gestió d'Ajuts Universitaris i de Recerca 2021_SGR_01186Asociación Española Contra el Cáncer Beca predoctoral 2019Instituto de Salud Carlos III PI18/00573Instituto de Salud Carlos III PI21/00294Instituto de Salud Carlos III PT20/00021Juan de la Cierva FJC2019-041213-IUniversitat de Lleida Predoctoral GrantsXarxa de Bancs de Tumors de Catalunya sponsored by Pla Director Oncologia de Catalunya (XBTC) B.0000682
6 · The paper itself

Abstract

Acral lentiginous melanoma (ALM) is a rare melanoma subtype primarily located in acral regions. However, ALMs exhibit a distinctive genetic profile characterized by a high number of copy number variations (CNVs) and limited point mutations. Late diagnosis and restricted therapeutic efficacy contribute to its poor prognosis. The secretome within the tumor microenvironment (TME) influences immune modulation and plays a vital role in melanoma progression. We aim to analyze the role of ALM secretome and CNVs profile with prognosis in primary ALM patients. Here, we demonstrated that high CNV burden (CNVsHigh) was associated with worse clinicopathological characteristics and poor prognosis. Furthermore, our study also revealed that conditioned media (CM) of CNVsHigh genetic profile ALM cell line was associated with pro-tumoral, pro-angiogenic, and immunosuppressive secretome profiles. In addition, CM of CNVsHigh cell lines in vitro promotes macrophage polarization to immunosuppressive phenotype. Moreover, we observed an increased presence of immunosuppressive tumor-associated macrophages (TAMs) at the invasive front (IF) of CNVsHigh ALM biopsies. This research reveals the adverse prognostic impact of CNVsHigh in ALM patients, establishing a novel link with a pro-tumor secretome, offering potential biomarkers for prognosis and personalized treatment to enhanced disease monitoring in ALM patients.

Indexed as

DNA Copy Number VariationsMelanomaSkin NeoplasmsTumor MicroenvironmentAdultAgedBiomarkers, TumorCell Line, TumorCulture Media, ConditionedFemaleHumansMaleMiddle AgedPrognosisTumor-Associated MacrophagesBiomarkers, TumorCulture Media, Conditionedacral lentiginous melanomacopy number variationprognosissecretometumor microenvironment

Identifiers

PMID40362334
PMCPMC12071846

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.